The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain.” The AHA provided a statement for the hearing that shared concerns on issues such as efforts to weaken the 340B Drug Pricing Program, drug shortages and other drug supply chain disruptions, and private-payer policies undermining access and patient safety. The AHA made a series of recommendations to Congress, including opposing efforts to move 340B pricing to a rebate model, enacting policies to improve medication and device access, and prohibiting private-payer policies that require hospitals to obtain clinician-administered drugs through insurer-selected specialty pharmacies rather than through their own hospital pharmacy systems. 

Headline
The Senate Appropriations Committee Nov. 17 released its version of the fiscal year 2027 appropriations bill for the departments of Labor, Health and Human…
Headline
The AHA and its co-plaintiffs Nov. 16 filed a reply brief urging a federal court to block implementation of the Health Resources and Services Administration’s…
Headline
The U.S. District Court for the Eastern District of Pennsylvania Nov. 4 ruled in favor of Jefferson Health in granting a public resolution to determine the…
Blog
Public
A recent issue brief from the Department of Health and Human Services asserts that Medicaid hospital provider taxes raise employer-sponsored insurance premiums…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…